Vineet Laboratories Ltd
Incorporated in 2003, Vineet Laboratories Ltd is in designing, developing, manufacturing of API Intermediates and Bulk Drugs
- Market Cap ₹ 65.2 Cr.
- Current Price ₹ 34.0
- High / Low ₹ 43.8 / 23.9
- Stock P/E
- Book Value ₹ 7.40
- Dividend Yield 0.00 %
- ROCE -28.0 %
- ROE -89.5 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 4.59 times its book value
- Company has low interest coverage ratio.
- Promoter holding has decreased over last quarter: -6.48%
- Promoter holding is low: 5.98%
- Company has a low return on equity of -21.7% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|
| 0 | 243 | 191 | 212 | 151 | 75 | 55 | |
| 0 | 235 | 178 | 205 | 143 | 91 | 60 | |
| Operating Profit | -0 | 8 | 13 | 8 | 7 | -16 | -5 |
| OPM % | 3% | 7% | 4% | 5% | -22% | -9% | |
| 0 | 0 | 0 | 0 | 0 | 2 | 1 | |
| Interest | 0 | 3 | 2 | 3 | 5 | 4 | 5 |
| Depreciation | 0 | 2 | 2 | 2 | 3 | 2 | 3 |
| Profit before tax | -0 | 4 | 9 | 2 | 0 | -21 | -11 |
| Tax % | 0% | 56% | 29% | 38% | -183% | -3% | |
| -0 | 2 | 7 | 1 | 1 | -20 | -10 | |
| EPS in Rs | -0.11 | 0.93 | 3.46 | 0.65 | 0.54 | -10.52 | -5.28 |
| Dividend Payout % | 0% | 0% | 14% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -27% |
| TTM: | -44% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -31% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -6% |
| 1 Year: | 27% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | -9% |
| 3 Years: | -22% |
| Last Year: | -89% |
Balance Sheet
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.41 | 9 | 9 | 9 | 9 | 9 | 9 |
| Reserves | -0 | 17 | 24 | 24 | 26 | 5 | 5 |
| 0 | 12 | 27 | 31 | 44 | 40 | 43 | |
| 0 | 70 | 74 | 51 | 38 | 40 | 34 | |
| Total Liabilities | 0 | 109 | 133 | 116 | 117 | 95 | 91 |
| 0 | 20 | 21 | 27 | 27 | 25 | 24 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 89 | 112 | 89 | 90 | 69 | 66 | |
| Total Assets | 0 | 109 | 133 | 116 | 117 | 95 | 91 |
Cash Flows
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 0 | 27 | 8 | -10 | -7 | 11 | |
| 0 | -8 | -4 | -7 | -2 | -3 | |
| 0 | 19 | 12 | 0 | 8 | -8 | |
| Net Cash Flow | 0 | 38 | 16 | -16 | -0 | 0 |
| Free Cash Flow | 0 | 27 | 8 | -17 | -9 | 10 |
| CFO/OP | 0% | 327% | 82% | -87% | -88% | -71% |
Ratios
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Debtor Days | 64 | 69 | 60 | 77 | 64 | |
| Inventory Days | 73 | 109 | 98 | 158 | 260 | |
| Days Payable | 114 | 161 | 74 | 103 | 175 | |
| Cash Conversion Cycle | 23 | 17 | 84 | 131 | 150 | |
| Working Capital Days | 14 | -19 | 21 | 28 | -37 | |
| ROCE % | 34% | 23% | 9% | 7% | -28% |
Insights
In beta| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Debtors Turnover Ratio Ratio |
|
||||
| Headcount (Total Employees) Number |
|||||
| Key Product Dispatch Quantity - N-Butyl Lithium (NBL) kgs |
|||||
| Net Capital Turnover Ratio Ratio |
|||||
| Total Number of Batches Produced Number |
|||||
| Total Production Volume (Quantity Dispatched) kgs |
|||||
Extracted by Screener AI
Documents
Announcements
-
Outcome Of Board Meeting Held On May 30, 2026 - Deferment Of Consideration Of Audited Standalone Financial Results
4h - Board deferred FY26 audited standalone results; Company Secretary and Compliance Officer resigned.
-
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
1d - Mr. Ramesh Kumar Bandari resigned as Company Secretary and Compliance Officer, effective May 29, 2026.
-
Board Meeting Intimation for To Consider And Approve The Audited Standalone Financial Results Of The Company For The Fourth Quarter And The Financial Year Ended March 31St, 2026.
26 May - Board meeting on May 30, 2026 to approve audited standalone financial results for FY2026.
-
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
15 May - Crisil report for Q3 FY26 rights issue proceeds: Rs 1,352.24 lakh utilized, no deviation reported.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
21 Apr - Submitted Regulation 74(5) certificate for Q4 and FY2026; no demat/remat requests received.
Business Overview[1]
The Co. manufactures and distributes pharmaceuticals, bulk drugs, chemicals, and pesticides. The company also conducts R&D across the biotechnology, healthcare, and industrial sectors, specializing in the export and import of various chemical formulations.